Targeted Therapy
Approved for: NSCLC
Biomarker: ALK, ROS1

Crizotinib (Xalkori) approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is ALK positive or ROS1 positive and has metastasized (spread to other parts of the body).